Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Determining the clinical relevance of the interaction between enzalutamide and the opioid morphine and the DOAC edoxaban to improve rational pharmacological care of patients with prostate cancer Vaststellen van de klinische relevantie van de interactie tussen enzalutamide en het opiaat morfine en de DOAC edoxaban om rationaal farmacologische zorg te verbeteren bij patiËnten met prostaat kanker

Trial Profile

Determining the clinical relevance of the interaction between enzalutamide and the opioid morphine and the DOAC edoxaban to improve rational pharmacological care of patients with prostate cancer Vaststellen van de klinische relevantie van de interactie tussen enzalutamide en het opiaat morfine en de DOAC edoxaban om rationaal farmacologische zorg te verbeteren bij patiËnten met prostaat kanker

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Edoxaban; Morphine
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Acronyms MIND THE GAP

Most Recent Events

  • 27 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top